Nursing Pharmacology Chapter 33-34: Cancer Chemotherapy Drug Practice Questions
Click on the correct answer.
1 / 10
Resistance to platinum analog anticancer drugs:
Carboplatin and cisplatin exhibit cross-resistance
Platinum-DNA adduct repair requires the nucleotide excision repair (NER) pathway
Both
Neither
Basal-type breast cancer (BRCA1 + BRCA2 mutations) appears uniquely sensitive to cisplatin due to upregulation of apototic pathways.
True
False
Cisplatin when combined with bleomycin, ifosfamide, etoposide, or vinblastine is curative in about 90% of individuals with testicular cancer.
True
False
Neurotoxicity, anadverse effect, dose-limiting in nature, is associated with this platinum analog anticancer agent.
Carboplatin
Cisplatin
Oxaliplatin
All of the above
Loss (or inhibition) of the nucleotide excision repair pathway increases cisplatin sensitivity in ovarian cancer.
True
False
Clearance of platinum analogues e.g. cisplatin:
Renal; urinary excretion
Dosage adjustment needed for patients with renal insufficiency
Both
Neither
Tumor cells that develop resistance to carboplatin or cisplatin are likely to be cross resistant to oxaliplatin.
True
False
Initial FDA-approved use of oxaliplatin was as a second-line therapy for metastatic colorectal cancer. Oxaliplatin in this setting was combined with 5-fluorouracil in the FOLFOX treatment regimen.
True
False
Resistance to this platinum analog anticancer drug appears to require DNA mismatch repair proteins (MMR proteins; hMLH1, hMLH2 or hMSH6):
Cisplatin
Oxaliplatin
Both
Neither
Carboplatin:
Primary dose-limiting toxic effect is myelosuppression.
Frequently used in transplant protocols to manage hematologic cancers refractory to other approaches
